|
|
||||||||
as a therapeutic target in cancer
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
(Requests for offprints should be addressed to D P McDonnell; Email: donald.mcdonnell{at}duke.edu)
This paper was presented at the 2nd Tenovus/AstraZeneca Workshop, Cardiff (2006). AstraZeneca supported the meeting and the Welsh School of Pharmacy, Cardiff University has supported the publication of these proceedings.
The orphan receptor estrogen-related receptor
(ERR
) is a member of the nuclear receptor superfamily of ligand-regulated transcription factors. This protein is structurally most related to the canonical estrogen receptor and has been shown to modulate estrogen signaling in some contexts. These observations have heightened interest in ERR
as a therapeutic target in both breast and ovarian cancer and in other estrogenopathies. This review details our present understanding of ERR
action with a view to highlight specific aspects of its signal-transduction pathway in breast cancer that may be amenable to pharmaceutical manipulation.
This article has been cited by other articles:
![]() |
X. Kong, H. Fan, X. Liu, R. Wang, J. Liang, N. Gupta, Y. Chen, F. Fang, and Y. Chang Peroxisome Proliferator-Activated Receptor {gamma} Coactivator-1{alpha} Enhances Antiproliferative Activity of 5'-Deoxy-5-Fluorouridine in Cancer Cells through Induction of Uridine Phosphorylase Mol. Pharmacol., October 1, 2009; 76(4): 854 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF] |
||||
![]() |
Consensus Statement Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S1 - S2. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |